Endocrine Abstracts

Background: In patients with type 1 diabetes (T1D), arterial stiffness is a potential alternative biomarker for cardiovascular (CV) risk as it has recently shown important prognostic value in the development of CVD that is independent from traditional risk factors. Glycemic control by means of HbA1c is a main determinant of arterial stiffness progression, however the relationship with continuous glucose monitoring (CGM)-derived parameters such as time in range (TIR) has not be...

Introduction: Thyroid disorders affect metabolism and body composition; however, literature data have been conflicting on whether this is also the case for thyroid hormone levels within the euthyroid range. Therefore, we have investigated the relationship between indices of thyroid status and both body composition and metabolic parameters in a population of healthy euthyroid men.Methods: Healthy male siblings (n=941, 25–45 years, median BMI 2...

Background and aims: HbA1c as a gold-standard measure for glycaemic control has been criticized for several years: lacking the ability to capture hypoglycaemia, time spent in different glucose ranges or to reflect glycaemic variability (GV) are frequently reported shortcomings. Continuous glucose monitoring (CGM) can overcome this, and several new CGM-derived parameters have been proposed to provide additional insights, with the concept of time in range (TIR) and other paramet...

Aims or Objectives: We here describe a role for the kinase thousand and one kinase (TAOK) 3 as a modulator of insulin resistance. TAOK3 is one of three members of the TAOK family of kinases, which are classified within the Ste20-like kinases as mitogen activated protein kinase 4 kinases. TAOK3 was identified in a RNAi library screening in C. elegans as a target molecule that could revert an insulin resistance-like state induced by a daf-2 mutation (Devgen, Ghent). Mor...

Background and aims: So far, HbA1c is the only metric of glucose control showing a strong association with chronic complications. However, it does not reflect short-term glycemic variability nor provides guidance in decreasing risk of hypoglycemia. More widespread use of continuous glucose monitoring (CGM) has changed the way people with type 1 diabetes (T1D) manage their glycemia by providing information about glycemic variability and time spent in different glucose ranges.</...